162 related articles for article (PubMed ID: 16499661)
1. Altered expression of CDX2 in colorectal cancers.
Choi BJ; Kim CJ; Cho YG; Song JH; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
APMIS; 2006 Jan; 114(1):50-4. PubMed ID: 16499661
[TBL] [Abstract][Full Text] [Related]
2. [Expression of Cdx2 protein in colorectal cancer].
Pack JH; Kim TD; Oh HA; Lee EJ; Kim JW; Jang BI; Kim TN; Jung MK; Bae YK
Korean J Gastroenterol; 2005 Sep; 46(3):204-10. PubMed ID: 16179840
[TBL] [Abstract][Full Text] [Related]
3. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas.
Sen A; Mitra S; Das RN; Dasgupta S; Saha K; Chatterjee U; Mukherjee K; Datta C; Chattopadhyay BK
Indian J Pathol Microbiol; 2015; 58(2):158-62. PubMed ID: 25885126
[TBL] [Abstract][Full Text] [Related]
4. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
Bakaris S; Cetinkaya A; Ezberci F; Ekerbicer H
Histol Histopathol; 2008 Sep; 23(9):1043-7. PubMed ID: 18581275
[TBL] [Abstract][Full Text] [Related]
5. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
[TBL] [Abstract][Full Text] [Related]
6. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.
Olsen J; Espersen ML; Jess P; Kirkeby LT; Troelsen JT
Surg Oncol; 2014 Sep; 23(3):167-76. PubMed ID: 25126956
[TBL] [Abstract][Full Text] [Related]
7. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
Witek ME; Nielsen K; Walters R; Hyslop T; Palazzo J; Schulz S; Waldman SA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8549-56. PubMed ID: 16361536
[TBL] [Abstract][Full Text] [Related]
8. Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2.
Modica S; Morgano A; Salvatore L; Petruzzelli M; Vanier MT; Valanzano R; Esposito DL; Palasciano G; Duluc I; Freund JN; Mariani-Costantini R; Moschetta A
Gut; 2009 Sep; 58(9):1250-9. PubMed ID: 19221108
[TBL] [Abstract][Full Text] [Related]
9. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer.
Hong KD; Lee D; Lee Y; Lee SI; Moon HY
Am Surg; 2013 Apr; 79(4):353-60. PubMed ID: 23574843
[TBL] [Abstract][Full Text] [Related]
10. Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions.
Qin R; Wang NN; Chu J; Wang X
World J Gastroenterol; 2012 Jul; 18(25):3296-302. PubMed ID: 22783055
[TBL] [Abstract][Full Text] [Related]
11. CDX2 expression is increased in gastric cancers with less invasiveness and intestinal mucin phenotype.
Ha Kim G; Am Song G; Youn Park D; Han Lee S; Hyun Lee D; Oh Kim T; Jae Jo H; Heo J; Hwan Kang D; Cho M
Scand J Gastroenterol; 2006 Aug; 41(8):880-6. PubMed ID: 16803685
[TBL] [Abstract][Full Text] [Related]
12. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
[TBL] [Abstract][Full Text] [Related]
13. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
15. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
16. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation downregulates CDX2 expression in colorectal carcinomas.
Kawai H; Tomii K; Toyooka S; Yano M; Murakami M; Tsukuda K; Shimizu N
Oncol Rep; 2005 Mar; 13(3):547-51. PubMed ID: 15706431
[TBL] [Abstract][Full Text] [Related]
18. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
Fan Z; Li J; Dong B; Huang X
Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
[TBL] [Abstract][Full Text] [Related]
19. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
Lugli A; Tzankov A; Zlobec I; Terracciano LM
Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cadherin-17 expression between primary colorectal adenocarcinomas and their corresponding metastases: the possibility of a diagnostic marker for detecting the primary site of metastatic tumour.
Park JH; Seol JA; Choi HJ; Roh YH; Choi PJ; Lee KE; Roh MS
Histopathology; 2011 Jan; 58(2):315-8. PubMed ID: 21323956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
